Cost-effectiveness of metformin plus vildagliptin versus metformin plus sulphonylurea for the treatment of type 2 diabetes: a real-life perspective

被引：0
|
作者：
Viana, R. [1 ]
Agrawal, R. [2 ]
Ong, S. -H. [1 ]
Paldanius, P. M. [1 ]
Partha, G. [2 ]
机构：
[1] Novartis Pharma AG, Basel, Switzerland
[2] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India
来源：
DIABETOLOGIA | 2015年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
994
引用
收藏
页码：S482 / S482
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of metformin plus vildagliptin versus metformin plus sulphonylurea for the treatment of type 2 diabetes patients in Portugal
    Viriato, D.
    Calado, F.
    Gruenberger, J-B.
    Ong, S. H.
    Carvalho, D.
    Silva-Nunes, J.
    Johal, S.
    Viana, R.
    [J]. DIABETOLOGIA, 2014, 57 : S328 - S328
  • [2] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) AS AN AD-ON TO METFORMIN OR METFORMIN PLUS SULPHONYLUREA IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN SPAIN
    Nielsen, A. T.
    Pitcher, A.
    Lovato, E.
    Schubert, A.
    Hemels, M.
    Neslusan, C.
    Gonzalez, B.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A62 - A62
  • [3] THE LONG-TERM COST-EFFECTIVENESS OF VILDAGLIPTIN plus METFORMIN THERAPY RELATIVE TO COMPARATOR SULFONYLUREA plus METFORMIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES IN CHINA
    Xu, J.
    [J]. VALUE IN HEALTH, 2020, 23 : S131 - S131
  • [4] Cost-effectiveness analysis of metformin plus dipeptidyl peptidase-4 inhibitors compared to metformin plus sulfonylureas for treatment of type 2 diabetes
    Kwon, Christina S.
    Seoane-Vazquez, Enrique
    Rodriguez-Monguio, Rosa
    [J]. BMC HEALTH SERVICES RESEARCH, 2018, 18
  • [5] A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus
    Tandon, Tanya
    Dubey, Ashok K.
    Srivastava, Saurabh
    Manocha, Sachin
    Arora, Ekta
    Hasan, Nazer
    [J]. JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2019, 8 (03) : 955 - 959
  • [6] COST-EFFECTIVENESS OF SITAGLIPTIN COMPARED TO SULPHONYLUREA AS AN ADD-ON TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES IN GREECE
    Athanasakis, K.
    Zhuo, J.
    Chen, J.
    Boubouchairopoulou, N.
    Tarantilis, F.
    Papageorgiou, M.
    Retsa, P.
    Brandtmuller, A.
    Tunceli, K.
    Karokis, A.
    Kyriopoulos, J.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A608 - A608
  • [7] THE COST-EFFECTIVENESS OF SAXAGLIPTIN WHEN ADED TO METFORMIN AND SULPHONYLUREA IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN SPAIN
    Sanchez-Covisa, J.
    Franch, J.
    Mauricio, D.
    Lopez-Martinez, N.
    Chuang, L. H.
    Capel, M.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A350 - A350
  • [8] Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus
    Guarino, Elisa
    Nigi, Laura
    Patti, Aurora
    Fondelli, Cecilia
    Dotta, Francesco
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (09) : 1377 - 1384
  • [9] The cost-effectiveness of canagliflozin versus sulphonylurea in patients with Type 2 diabetes with inadequate control on metformin monotherapy in the UK
    Schroeder, M.
    Johansen, P.
    Willis, M.
    Neslusan, C.
    [J]. DIABETIC MEDICINE, 2015, 32 : 205 - 205
  • [10] Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: An application of the CORE Diabetes Model in type 2 diabetes
    Palmer, AJ
    Roze, S
    Lammert, M
    Valentine, WJ
    Minshall, ME
    Nicklasson, L
    Gall, MA
    Spinas, GA
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 : S41 - S51
12345